17 GHP International Life Sciences Awards 2023 arinova is dedicated to the development and production of high purity seaweed extracts for the betterment of human health. The company specialises in the research, development and manufacture of fucoidan compounds – highly bioactive polysaccharides derived from select species of brown seaweed. Sustainably sourced and clinically validated, Maritech® organic fucoidans are high purity seaweed extracts sought after by some of the world’s most trusted healthcare brands. They are included as premium ingredients in market-leading nutritional supplements, medical devices, functional foods and beverages, skincare and dermatological formulations, and animal health products. Company CEO, Mr Paul Garrott, explains, “There is rapidly growing interest in marine bioproducts and for good very reason. Superior ingredients in this category tick all the boxes – they are natural, sustainably sourced, supported by an extensive dossier of scientific evidence and have global regulatory acceptance. Maritech® organic fucoidans represent all this and more. They are ideal for new product innovators seeking novel ingredients with a clear point of differentiation.” “The benefits of fucoidans are well understood in countries such as Japan and Korea,” continued Garrott. “But it has only been in recent years that awareness has been building in the US and Europe. This aligns not only with the granting of regulatory approvals, but also the growing investment in fucoidan research. There are now more than 2500 scientific papers attesting to the bioactive properties fucoidans … and Marinova is continuing to lead the way.” “Maritech® fucoidan extracts are included in dietary supplements that target a diverse range of human health conditions. Immune support, gut and digestive health, and healthy ageing are key focus areas,” said Garrott. “Marinova is continually investing in rigorous scientific research including comprehensive in vitro investigations, animal studies and human clinical trials. The company is a partner in Australia’s Marine Bioproducts CRC – a dynamic consortium 70 partners involved in a $270 million dollar R&D program. Australia is very serious about the future for high quality marine bioproducts.” As the global leader in fucoidan science, Marinova is also the supplier of choice to world-renowned research institutions. “Our highly characterised fucoidan fractions are well-suited to medical device applications and pharmaceutical research,” explained Garrott. “Marinova also possesses the unique ability to isolate distinct fucoidan compounds with enhanced efficacy and superior compatibility with other biomaterials and therapeutic agents. Marinova is at the forefront of developing discrete fucoidans for medical research. The company’s team of scientists understand the unique physicochemical properties of fucoidan extracts and how these may be tailored to influence uptake and achieve targeted therapeutic effects.” Maritech® fucoidan is the world’s only high purity, certified organic fucoidan with global regulatory acceptance. “This is by virtue of our proprietary Maritech® extraction process,” explained Garrott. “Fucoidans have traditionally been precipitated from crude extracts using solvents. This may lead to contaminants being present in the final extract. Fucoidans manufactured in this way can suffer from many shortfalls. Their quality can be inconsistent, their chemical integrity may be compromised and – most importantly – their bioactivity may be affected.” The Maritech® extraction technology, developed and used exclusively by Marinova, overcomes these problems. Unique ‘green chemistry’ processes avoid organic solvents and produces fucoidan extracts that remain unadulterated in chemical structure and free from solvent residues. The mild, aqueous process also ensures the resulting extracts comply with the most rigorous quality standards and regulatory requirements. Garrott offers useful advice to those unfamiliar with fucoidan. “Extensive research tells us there are two critical factors that determine fucoidan efficacy. Firstly, the seaweed species from which the fucoidan has been derived and secondly, the method of extraction. It is crucial you question any potential fucoidan manufacturer about those two elements.” Marinova’s core fucoidan ingredients are extracted from two species of seaweed, Undaria pinnatifida (wakame) and Fucus vesiculosus (bladderwrack). “Fucoidans from these two species have been the most widely researched,” said Garrott. “They are also rapidly renewable marine resources that we are able to hand harvest – sustainably and ethically. In fact, the entire process from harvest through to the capture and reuse of waste places us on the cusp of being a genuine zero-waste operation. Importantly, our Maritech® extracts are the only certified organic, high purity fucoidan ingredients with global regulatory acceptance.” The future of Maritech® organic fucoidans is bright. “We are currently scaling up both our research investment and our production capacity here in Australia,” finished Garrott. “There are not many natural, bioactive ingredients that are supported by this volume of scientific evidence and demand for high purity fucoidan is rising significantly. We have some exciting research collaborations underway across the globe that have the potential to reshape human health and that’s rewarding indeed.” Company: Marinova Pty Ltd Email: [email protected] Website: www.maritechfucoidan.com.au M Feb23194 Health & Wellness Ingredient Innovator of the Year 2023 Australian biotechnology leader Marinova Pty Ltd is making waves in global healthcare. Its unique portfolio of bioactive seaweed extracts is the result of two decades of innovative R&D. Maritech® organic fucoidan represents the future of natural and sustainably sourced ingredients with proven efficacy.